Search company, investor...

Intercept Pharmaceuticals

interceptpharma.com

Founded Year

2002

Stage

PIPE | IPO

Total Raised

$121M

Market Cap

0.76B

Stock Price

17.94

Revenue

$0000 

About Intercept Pharmaceuticals

Intercept is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe, and Canada.

Headquarters Location

10 Hudson Yards 37th Floor

New York, New York, 10013,

United States

844-782-4278

Missing: Intercept Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Intercept Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Intercept Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Intercept Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Intercept Pharmaceuticals Patents

Intercept Pharmaceuticals has filed 73 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Hepatology
  • Intracellular receptors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/23/2018

10/18/2022

Transcription factors, Polygons, Intracellular receptors, G protein coupled receptors, Progestogens

Grant

Application Date

7/23/2018

Grant Date

10/18/2022

Title

Related Topics

Transcription factors, Polygons, Intracellular receptors, G protein coupled receptors, Progestogens

Status

Grant

Latest Intercept Pharmaceuticals News

Fair chance of nod for first NASH therapy in USA, says GlobalData

Jan 26, 2023

Pharma industry analyst GlobalData has highlighted the strength of data supporting a submission from US biotech Intercept Pharmaceuticals (Nasdaq: ICPT) in non-alcoholic steatohepatitis (NASH). Intercept Pharmaceuticals (Nasdaq: ICPT) is developing obeticholic acid (OCA) as a treatment for people with pre-cirrhotic liver fibrosis due to NASH, and the US regulator is currently reviewing data from the trial program. The company has had a bumpy ride to… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK

Intercept Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Intercept Pharmaceuticals founded?

    Intercept Pharmaceuticals was founded in 2002.

  • Where is Intercept Pharmaceuticals's headquarters?

    Intercept Pharmaceuticals's headquarters is located at 10 Hudson Yards, New York.

  • What is Intercept Pharmaceuticals's latest funding round?

    Intercept Pharmaceuticals's latest funding round is PIPE.

  • How much did Intercept Pharmaceuticals raise?

    Intercept Pharmaceuticals raised a total of $121M.

  • Who are the investors of Intercept Pharmaceuticals?

    Investors of Intercept Pharmaceuticals include Genextra, OrbiMed Advisors, Balyasny Asset Management and JAFCO Life Science Investment.

  • Who are Intercept Pharmaceuticals's competitors?

    Competitors of Intercept Pharmaceuticals include Immunomic Therapeutics, Constellation Pharmaceuticals, CVRx, Intarcia Therapeutics, Metabolic Solutions Development, Rhythm Pharmaceuticals, PrevaCept Infection Control, VentiRx Pharmaceuticals, AnaptysBio, Kolltan Pharmaceuticals and 34 more.

Compare Intercept Pharmaceuticals to Competitors

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

A
Aderis Pharmaceuticals

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

K
KeyNeurotek Pharmaceuticals

KeyNeurotek Pharmaceuticals is a clinical stage small molecule company focused on autoimmune and CNS diseases.

C
CMP

CMP Therapeutics has developed a treatment for regulating and stimulating the immune system. The lead product is in Phase II clinical trials for allergic disorders. Other pipeline products have shown through stimulation of the immune system to protect against viruses and bacteria.

A
Asterion

Asterion is a manufacturer of analog semiconductors.

Icagen Logo
Icagen

Icagen partners with pharmaceutical and biotechnology companies to offer scientific expertise and access to technologies for ion channel and transporter drug discovery and development. The Icagen team has experience advancing molecules from drug discovery to clinical development across multiple therapeutic areas and ion channel classes. Icagen's tool box comprises a range of cell lines and technologies for ion channel and transporter research, capped by the label-free XRpro platform. XRpro technology, based on X-ray fluorescence, enables high throughput assessment of ion channels and transporters, including challenging systems with high therapeutic interest.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.